CRIS Current Research Information System

PAPAYANNIDIS, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.935
AS - Asia 15.582
EU - Europa 14.048
AF - Africa 1.178
SA - Sud America 976
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 16
Totale 48.763
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.739
CN - Cina 4.701
SG - Singapore 4.064
GB - Regno Unito 3.925
VN - Vietnam 3.407
SE - Svezia 2.215
IT - Italia 2.091
DE - Germania 1.737
HK - Hong Kong 1.153
IN - India 902
RU - Federazione Russa 731
BR - Brasile 710
FR - Francia 582
NL - Olanda 554
IE - Irlanda 506
KR - Corea 466
ZA - Sudafrica 325
UA - Ucraina 297
TG - Togo 289
EE - Estonia 262
FI - Finlandia 230
CI - Costa d'Avorio 220
JP - Giappone 212
CH - Svizzera 202
NG - Nigeria 170
GR - Grecia 162
BG - Bulgaria 156
JO - Giordania 150
AR - Argentina 135
CA - Canada 134
SC - Seychelles 130
IR - Iran 112
BE - Belgio 90
ID - Indonesia 85
AT - Austria 75
TR - Turchia 62
PL - Polonia 61
BD - Bangladesh 50
ES - Italia 49
MX - Messico 42
EC - Ecuador 33
UZ - Uzbekistan 33
IQ - Iraq 30
LB - Libano 25
AU - Australia 23
PH - Filippine 23
CL - Cile 21
LT - Lituania 18
PY - Paraguay 18
CO - Colombia 17
HR - Croazia 17
MY - Malesia 16
CZ - Repubblica Ceca 14
PE - Perù 14
RO - Romania 14
EU - Europa 12
VE - Venezuela 12
PK - Pakistan 11
AE - Emirati Arabi Uniti 9
EG - Egitto 9
KZ - Kazakistan 9
MA - Marocco 9
MK - Macedonia 9
TN - Tunisia 9
TW - Taiwan 8
UY - Uruguay 8
KG - Kirghizistan 7
PT - Portogallo 7
RS - Serbia 7
IL - Israele 6
SK - Slovacchia (Repubblica Slovacca) 6
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
DZ - Algeria 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
QA - Qatar 5
SA - Arabia Saudita 5
AL - Albania 4
GY - Guiana 4
LV - Lettonia 4
NP - Nepal 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
BO - Bolivia 3
BY - Bielorussia 3
DK - Danimarca 3
KE - Kenya 3
PA - Panama 3
BH - Bahrain 2
BN - Brunei Darussalam 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HN - Honduras 2
HU - Ungheria 2
KH - Cambogia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 48.733
Salva come PNG Salva come JPEG
Città #
Southend 3.646
Singapore 2.826
Ashburn 1.829
Chandler 1.626
Fairfield 1.483
Dong Ket 1.344
Hong Kong 1.142
Hefei 963
Houston 889
Wilmington 794
Beijing 784
Woodbridge 737
Ann Arbor 708
Seattle 682
Princeton 654
Santa Clara 646
Cambridge 513
Dublin 502
Boardman 498
Ho Chi Minh City 436
Seoul 427
Bologna 367
Hanoi 339
Westminster 322
Nanjing 315
Lomé 289
Padova 285
Medford 230
Dallas 226
Los Angeles 224
New York 223
Abidjan 220
Bern 167
Milan 164
Helsinki 158
Shenyang 155
Sofia 152
Amman 149
Jinan 148
Tokyo 147
Saint Petersburg 143
Berlin 140
Munich 140
Redondo Beach 135
Buffalo 130
Redmond 126
Hebei 120
Nanchang 113
Abeokuta 111
São Paulo 106
Turin 106
Bremen 105
Frankfurt am Main 99
Changsha 97
San Diego 97
Bengaluru 92
Redwood City 91
Brussels 89
Florence 86
Guangzhou 79
Falls Church 77
Tianjin 75
Zhengzhou 74
Jacksonville 71
Jiaxing 70
Shanghai 67
Rome 62
Norwalk 57
Toronto 53
Falkenstein 51
Jakarta 50
Haiphong 48
Hangzhou 47
Nuremberg 46
Vienna 46
Phoenix 44
Ningbo 43
Turku 43
Haikou 42
Chicago 40
Mountain View 40
Biên Hòa 39
Taiyuan 39
London 36
Tongling 36
Amsterdam 34
Hyderabad 34
Paris 34
Brooklyn 32
Da Nang 32
Athens 31
Mülheim 31
Warsaw 31
Kunming 30
Dearborn 29
Fuzhou 29
Taizhou 29
Düsseldorf 28
Tehran 28
Thái Nguyên 28
Totale 31.370
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 626
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 331
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 318
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 314
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 312
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 304
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 296
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 285
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 283
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 275
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 269
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 257
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 254
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 239
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 238
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 233
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 229
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 224
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 223
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 219
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 217
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 216
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 213
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 211
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 210
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 210
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 209
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 208
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 206
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia 205
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 205
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 201
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 200
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 200
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 200
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 199
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 197
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 195
A case report of acute myeloid leukemia and neurofibromatosis 1 195
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 194
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 194
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 193
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 193
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 193
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 192
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 190
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 187
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 186
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 184
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 182
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 182
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 182
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 182
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 181
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 181
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 180
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma 180
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 180
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 178
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 178
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 178
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 176
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 174
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 174
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 174
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 174
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 171
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 171
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 169
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 169
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 168
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 168
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 167
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 166
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 166
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 166
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 166
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 165
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 165
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 165
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 165
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 164
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 163
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 162
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 162
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 161
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 161
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 161
Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study 161
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 160
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 160
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 160
Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. 160
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 160
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 159
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 158
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 158
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 157
Clec12a: A new AML stem cell-associated antigen 157
Totale 20.160
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.921
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.921
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.727 0 0 0 0 0 218 106 306 477 198 206 2.216
2021/20226.614 650 151 413 592 663 438 133 425 345 463 1.167 1.174
2022/20237.108 820 1.089 362 913 532 519 249 400 1.148 159 554 363
2023/20242.002 94 296 109 184 133 422 120 142 119 129 134 120
2024/20258.374 325 1.249 662 538 1.146 392 746 271 113 757 482 1.693
2025/20269.628 1.810 2.536 1.709 1.414 2.061 98 0 0 0 0 0 0
Totale 49.806